• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
Grand Rounds

Meis and PROLONG Trials: The Safety Profile for 17-OHPC used to Prevent Preterm Birth

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • 17-alpha-hydroxyprogesterone caproate (17-OHPC) has been used to prevent recurrent preterm birth since 2003, when the Meis trial was published showing its efficacy
    • A recently completed confirmatory trial, PROLONG, did not demonstrate similar efficacy
  • Sibai et al. (Journal of Perinatology, 2020) analyzed the 17-alpha-hydroxyprogesterone caproate (17-OHPC) safety data from both the Meis and PROLONG RCT datasets separately and also as an integrated dataset

METHODS:

  • Both Meis and PROLONG were multi-center, randomized, double-blind, placebo-controlled trials
  • Participants
    • Individuals with a history of spontaneous preterm birth (SPTB)
  • Interventions
    • 17-OHPC group: 250 mg weekly IM | Beginning at 16 to 20 weeks and continuing until 37 weeks of gestation or delivery
    • Placebo group

Study Design Related to Side Effects and Adverse Outcome Reporting

  • Meis:
    • Side effects not mentioned by the participant but recorded by study coordinator were documented as adverse events
    • Participants were asked open ended questions about symptoms as well as focused questions for specific adverse events
    • Serious events, including unexpected events, were recorded
  • PROLONG
    • Adverse events collected using standardized Good Clinical Practice guidelines
    • Participants were asked about change in well-being
    • Adverse events included if reported by the participants or the investigator | Investigator assessed causality

RESULTS:

  • Meis: 310 in 17-OHPC group | 153 in placebo group
  • PROLONG: 1130 in 17-OHPC | 578 in placebo group

Adverse Events

  • Adverse event profiles were similar between 17-OHPC and placebo groups in both studies
    • Meis: 57.7% vs 56.2%
    • PROLONG: 57.3% vs 57.8%
  • Serious adverse events were infrequent
  • Integrated maternal adverse events
    • GDM rate: No differences between groups
      • 17-OHPC group: 3.6%
      • Placebo: 3.8%
    • Similar findings for other adverse events, including hypertension and preeclampsia
  • Integrated perinatal adverse events: No statistical differences between groups
    • Miscarriage: 0.66 (95% CI, 0.25 to 1.78)
    • Stillbirth: 1.83 (95% CI, 0.68 to 4.91)
    • All fetal and neonatal death: 0.86 (95% CI, 0.53 to 1.41)

CONCLUSION:

  • 17-OHPC had a favorable safety profile in the integrated dataset, comparable to that of placebo
  • The authors also note that post-marketing safety data are consistent with the findings of this study

Learn More – Primary Sources:

Safety review of hydroxyprogesterone caproate in women with a history of spontaneous preterm birth

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone, with ObGFirst

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

FDA, SMFM and ACOG Respond to PROLONG Study Results: Does IM 17-OHPC Impact Preterm Delivery?
17-OHPC Treatment and Prevention of Preterm Birth: Does Timing Matter?
Do Progestogens for Preterm Birth Prevention Increase Risk of Gestational Diabetes?
Progesterone, Cerclage or Pessary for Prevention of Preterm Birth: A Comparison

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Download Your ObG App
HERE!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site